The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
Six months after evobrutinib’s two pivotal multiple sclerosis studies started enrolment, their comparator cohorts are overhauled.
Gilead and Galapagos's filgotinib might not be a match for Rinvoq in ulcerative colitis, while Menlo needs to prove serlopitant works after previous setbacks.
With eight phase III trials in three different indications, Lilly is investing heavily in mirikizumab. The first pivotal data, in psoriasis, will emerge soon.
The academic Dian-Tu study looks at anti-amyloid beta antibodies from Lilly and Roche; despite gantenerumab, hopes are being dialled back.
An upcoming study could show whether diabetes drugs like Novo’s Victoza might have an effect on slowing cognitive decline.
A strategic change towards Olympus's medical business, and particularly therapeutic procedures, has reignited growth. Next up: acquisitions.
The German start-up must navigate the hazards that have felled other surgical robot developers while simultaneously dealing with a more crowded market.
Livongo Health, which launched a highly successful IPO in July, claims to be one of the fastest-growing companies in Silicon Valley. Can it keep investors happy as growth…